Skip to main content
. Author manuscript; available in PMC: 2009 Dec 15.
Published in final edited form as: Cancer Res. 2008 Dec 15;68(24):10349–10357. doi: 10.1158/0008-5472.CAN-08-2754

Figure 2. Acquired UPD detected by 250K SNP-A may serve as a molecular marker for mutated genes in patients.

Figure 2

Topographical maps show regions of UPD in individual patients on chromosomes 9, 13 and 1 (Left). Yellow bars corresponding to the idiogram represent the regions affected for each patient. Individual diagnoses are listed to the right of the depicted lesion (disease sub-types are indicated in parentheses; for those patients who transformed to secondary AML, the initial presentation is given in parentheses). Red lines on the idiogram represent the physical location of the JAK2, FLT3 and c-MPL genes respectively. To the right: mutational screening of JAK2, FLT3, NRAS and c-MPL in patients with segmental UPD in the region of each gene confirms their homozygous status (note that sequencing analysis of NRAS exon 2 in patient 31 appears heterozygous due to the presence of non-clonal cells in the sample). Cartoons to the left of the maps represent the diploid chromosome set and identify the minimally overlapping region on each chromosome along with representative candidate genes in the region, regardless if the segment overlaps with known gene mutations or not. Gel images have been cropped and enhanced.